Literature DB >> 19122059

Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.

Kenji Hosoya1, William C Kisseberth, Francisco J Alvarez, Ana Lara-Garcia, Gillian Beamer, Paul C Stromberg, C Guillermo Couto.   

Abstract

The use of adjuvant 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; lomustine) to treat incompletely excised canine mast cell tumors (MCTs) has not been evaluated. Medical records of 12 dogs with grade 2 MCT treated with incomplete surgical excision and adjuvant CCNU and prednisone chemotherapy were reviewed. Local recurrence rate, metastasis rate, and survival time were evaluated. None of the dogs developed local recurrence or regional/ distant metastases. Two dogs developed fatal liver failure. The 1- and 2-year progression-free rates of surviving dogs were 100% and 77%, respectively. Postoperative adjuvant CCNU appears to be a useful alternative to radiation therapy for incompletely excised canine cutaneous MCTs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19122059     DOI: 10.5326/0450014

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  5 in total

1.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

2.  Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study).

Authors:  Galina V Ilyinskaya; Elena V Mukhina; Alesya V Soboleva; Olga V Matveeva; Peter M Chumakov
Journal:  Front Vet Sci       Date:  2018-06-04

Review 3.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

4.  Tolerability and Effects of 2-Aminoethyl Dihydrogen Phosphate in Dogs With Mast Cell Tumors.

Authors:  Eric Vieira Januário; Samanta Rios Melo; Durvanei Augusto Maria; Carla Aparecida Batista Lorigados; Aline Magalhães Ambrósio; Marcia Mery Kogika; Bruno Cogliati; Helio Junji Shimozako; Julia Maria Matera
Journal:  Front Vet Sci       Date:  2022-07-12

5.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.